Better A1C, weight seen with canagliflozin treatment

04/15/2013 | MedWire News (U.K.)

Type 2 diabetes patients who used canagliflozin as an add-on to metformin/sulfonylurea treatment showed better A1C levels and body weight at 52 weeks than those who took sitagliptin, according to a study in Diabetes Care. Researchers also found 47.6% of canagliflozin-treated patients attained an A1C of less than 7%, compared with 35.3% in the sitagliptin group.

View Full Article in:

MedWire News (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ